HBP
vs
S
S&P TSX Composite Index (Canada)
HBP
Over the past 12 months, HBP has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +125% compared to the S&P TSX Composite Index (Canada)'s +28% growth.
Stocks Performance
HBP vs S&P TSX Composite Index (Canada)
Performance Gap
HBP vs S&P TSX Composite Index (Canada)
Performance By Year
HBP vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Helix Biopharma Corp
Glance View
Helix BioPharma Corp. is an immuno-oncology company, which develops products for the treatment and prevention of cancer. The company is headquartered in Richmond Hill, Ontario and currently employs 10 full-time employees. Helix’s proprietary technological platforms include DOS47, V-DOS47 and L-DOS47. The DOS47 is an oncology platform that offers a debilitation and destruction of cancer cells by modulating the tumor microenvironment. DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2) and can be used in several types of solid tumors.
